Related Parties	12 Months Ended
Dec. 31, 2018
Related Parties
Related Parties	11. Related Parties As discussed in Note 1, on February 11, 2018, the Company entered into a joint venture agreement (the “JV Agreement”) with Shenzen Hepalink Pharmaceutical Group Co., Ltd., a Chinese entity (“Hepalink”) that is a related party and significant shareholder in the Company, pursuant to which we formed a Joint Venture company named Shenzen Arimab BioPharmaceuticals Co., Ltd., or SABC, a People’s Republic of China Company, for developing and commercializing products for infectious diseases in the greater China territories. It was agreed by the parties that the Company shall be reimbursed for certain legal and contract manufacturing expenses related to the clinical drug supply for a Phase 3 clinical study of AR-301. No amounts were reimbursed during 2018, however as of December 31, 2018, an outstanding receivable for reimbursable expenses in the amount of $360,000 was included in prepaid expenses and other current assets on the consolidated balance sheet.

Related Parties

12 Months Ended

Dec. 31, 2018

11. Related Parties

As discussed in Note 1, on February 11, 2018, the Company entered into a joint venture agreement (the “JV Agreement”) with Shenzen Hepalink Pharmaceutical Group Co., Ltd., a Chinese entity (“Hepalink”) that is a related party and significant shareholder in the Company, pursuant to which we formed a Joint Venture company named Shenzen Arimab BioPharmaceuticals Co., Ltd., or SABC, a People’s Republic of China Company, for developing and commercializing products for infectious diseases in the greater China territories. It was agreed by the parties that the Company shall be reimbursed for certain legal and contract manufacturing expenses related to the clinical drug supply for a Phase 3 clinical study of AR-301. No amounts were reimbursed during 2018, however as of December 31, 2018, an outstanding receivable for reimbursable expenses in the amount of $360,000 was included in prepaid expenses and other current assets on the consolidated balance sheet.